(MedPage Today) — Although most patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) didn’t respond adequately to the interleukin-17 (IL-17) inhibitor ixekizumab (Taltz), enough did that it should still be considered in such…
Source link : https://www.medpagetoday.com/rheumatology/arthritis/116666
Author :
Publish date : 2025-07-25 12:48:00
Copyright for syndicated content belongs to the linked Source.
